Clinical trial NCT04183595: NBMI Treatment in Patients With Mercury Toxicity
Official title: A Double-blinded, Randomized Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of N1, N3-bis-(2-Mercaptoethyl) Isophthalamide (NBMI) in the Reduction of Mercury Levels, in Subjects Exposed to Mercury in Colombia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
PHASE3
Conditions: Mercury Poisoning
Keywords: Exposure to mercury
NBMI
Lead sponsor: EmeraMed
Sponsor class: INDUSTRY
First posted: 2019-12-03
Enrollment: 116
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: One hundred and sixteen (116) participants will be randomized in a 1:1 ratio, to either one of the two arms of this trial.

This study will consist of 2 time periods/4 visits

1. Screening
2. Day 1 (Treatment start day, 7 days after visit 0)
3. Day 14 ± 3 days (Treatment end day)
4. Day 28 ± 3 days (Treatment drug-free follow-up end day)
Primary purpose: TREATMENT

Brief summary: NBMI (N1, N3-Bis-(2-Mercaptoethyl) Isophthalamide) is a new metal chelator drug proposed as an alternative to the current chelators, and it is widely different; compared to the current chelators, consisting of two cysteamine molecules coupled to a single molecule of dicarboxybenzoate. It is used as a chelating agent and has the designation of an orphan drug, in the EU and USA; in the EU it is used for the treatment of mercury toxicity. It is freely soluble in solutions of dimethylformamide (DMF), dimethyl sulfoxide (DMSO) and sodium hydroxide diluted NaOH, slightly soluble in methanol and acetone, and insoluble in water. Pre-clinical data indicates low to no toxicity, and that it reduces the toxicity associated with acute exposure to Hg2+.

No other chelator has been reported to prevent acute mercury toxicity with only one exposure to the chelator. It has the ability to penetrate cell membranes and cross the blood-brain barrier and chelate Hg2+ in a complex that eliminates the availability of Hg2+ and essentially eliminates toxic effects. The antioxidant properties of NBMI could also reduce the toxicity levels of hydroxyl free radicals immediately, upon entering cells suffering from oxidative stress. It is possible that the combined chelation of Hg2+ and the elimination of hydroxyl free radicals contribute significantly to the protective effects observed with the NBMI.

Previous clinical studies conducted in subjects of the Phase I and Phase II a studies conducted, did not show significant adverse events in patients intoxicated with mercury, all patients who received the study medication have tolerated it well, with only mild or moderate adverse events reported; None of these were considered related to the pharmacological treatment of the study. In addition, there is no potential identified with safety problems in laboratory tests, or vital signs evaluations.

The purpose of this Controlled Single-Center Double-Blind Crossover Clinical Trial Phase II b is to determine the efficacy, safety and tolerability of a 14 day 600mg / day of NBMI (N1, N2-bis-2-mercaptoethyl isophthalamide) Treatment, in the reduction of urinary mercury levels versus placebo, in accidentally exposed subjects to mercury in Colombia.

Detailed description: This is a Controlled Single-Center Double-Blind Crossover Clinical Trial Phase II b conducted in subjects with a history of chronic exposure to mercury in Colombia.

One hundred and sixteen patients (116) will be randomized in a 1:1 ratio, to either one of the two arms of this trial:

Group A:

NBMI (study drug) with an oral dose of 600 mg corresponding to 6 capsules of 100 mg of NBMI every 24 hours for 14 days.

Group B:

Placebo 6 capsules, every 24 hours for 14 days.

This study will consist of 2 time periods/4 visits

1. Screening
2. Day 1 (Treatment start day, 7 days after visit 0)
3. Day 14 ± 3 days (Treatment end day)
4. Day 28 ± 3 days (Treatment drug-free follow-up end day)

After Screening a computer-generated scrambling code will be used for allocation in blocks of 4 to the two treatments. During enrollment, the proportion of subjects with or without a history of previous treatment by chelating will be monitored.

The identity of patients included in the futility analysis will not be provided to the trial team, in order to preserve the blind aspect of the trial.

The trial will be interrupted if the difference between the groups of treatment in the primary assessment is significantly (α = 0.05 unilateral) less than 10% in favor of any of the arms.

A Data Monitoring Committee will be set up to monitor the safety and risk control general benefit. The committee's statistician and epidemiologist will carry out the evaluation.

The identity of the research product associated with each randomization number will be kept hidden for the trial team and for the patients.

The final analysis is planned for when 100% of the patients (116 patients) reach Day 28 of the study.

Eligibility criteria: Inclusion Criteria:

* Patients with a history of exposure to sources of mercury release by a known event of direct contact with metallic mercury.
* All subjects must have signed and dated an informed consent / assent consent form approved by the IRB in accordance with regulatory and institutional guidelines. This form must be obtained before performing any procedure related to the protocol that is not part of the subject's normal regimen.
* Under age minors must also have a psychological evaluation and documentation of Assent added to the Informed Consent Form.
* Patients with detectable urinary mercury levels \>10 ug / L at the time of screening.
* Patients must be willing and able to comply with clinic visits and all study-related procedures.
* Subjects with no previous chelation treatment or who have stopped receiving chelation treatment for more than 3 months will be enrolled.
* Participants must have controlled mercury levels, with no severe clinical manifestations, regardless of what the medical treatment may have been.

Exclusion Criteria:

* A history of known or suspected hypersensitivity or idiosyncratic reactions to the medication or test excipients. Patients with sulfa-drug sensitivity should be excluded from this study.
* Levels of mercury in urine / blood at the time of baseline measurement that are below detection threshold.
* Known history of drug addiction and / or alcoholism.
* Patients with a known medical condition that, in the opinion of the investigator, could increase the risk associated with participation in the study or with the administration of the study medication (s) under blinded conditions or interfere with the interpretation of the security results.
* Patients with major surgery or significant traumatic injury who have not recovered at least 14 days before the first dose of the study medications (s) under blind.
* Subjects with a condition requiring systemic corticosteroid therapy (\> 10 mg daily of prednisone equivalent) or other immunosuppressive medications within 14 days before or during treatment are excluded.
* Women with positive pregnancy test (urine sample) at the time of screening; or women who are breastfeeding, or are of childbearing age who disagree with taking contraceptives during treatment and until Day 28 after the last dose.

Primary outcomes:
measure: Measure the "Change in the subject's urine mercury levels"
timeFrame: Baseline (Before) treatment, Fourteen (14) days after the start of treatment, Fourteen (14) days after the end of treatment
Secondary outcomes:
measure: Measure the "Change in the subject's blood iron levels"
timeFrame: Baseline (Before) treatment, Fourteen (14) days after the start of treatment, Fourteen (14) days after the end of treatment
measure: Measure the "Change in the subject's blood glucose levels"
timeFrame: Baseline (Before) treatment, Fourteen (14) days after the start of treatment, Fourteen (14) days after the end of treatment
measure: Measure the "Change in the subject's renal function"
timeFrame: Baseline (Before) treatment, Fourteen (14) days after the start of treatment, Fourteen (14) days after the end of treatment
measure: Measure the "Frequency and Severity of Adverse Events"
timeFrame: From the first dose of study medication until the Day 56 visit.
measure: Measure subject's "Variations in Mental Response ".
timeFrame: Baseline (Before) treatment, Fourteen (14) days after the start of treatment, Fourteen (14) days after the end of treatment
measure: Measure subject's "Variations in General Clinical examination".
timeFrame: Baseline (Before) treatment, Fourteen (14) days after the start of treatment, Fourteen (14) days after the end of treatment
measure: Measure subject's "Variations in Height".
timeFrame: Baseline (Before) treatment, Fourteen (14) days after the start of treatment, Fourteen (14) days after the end of treatment
measure: Measure subject's "Variations in Weight".
timeFrame: Baseline (Before) treatment, Fourteen (14) days after the start of treatment, Fourteen (14) days after the end of treatment
measure: Mercury intoxication measured by Medical Intoxication Score
timeFrame: Baseline (Before) treatment, Fourteen (14) days after the start of treatment, Fourteen (14) days after the end of treatment
Other outcomes:
measure: Amalgam
timeFrame: Baseline (Before) treatment
measure: Diet
timeFrame: The patients will keep a food diary during the study (days 1-56).
Locations:
city: Barranquilla
country: Colombia
facility: Clínica de la Costa Ltda.
state: Atlántico
Study officials:
affiliation: Clínica De La Costa Ltda.
name: Andres Cadena-Bonfanti, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Cordy P, Veiga MM, Salih I, Al-Saadi S, Console S, Garcia O, Mesa LA, Velasquez-Lopez PC, Roeser M. Mercury contamination from artisanal gold mining in Antioquia, Colombia: The world's highest per capita mercury pollution. Sci Total Environ. 2011 Dec 1;410-411:154-60. doi: 10.1016/j.scitotenv.2011.09.006. Epub 2011 Oct 15.
citation: Erkek N, Senel S, Sarac A, Ertan U, Karacan CD. Being alive after a severe inorganic mercury intoxication. Eur J Pediatr. 2010 May;169(5):625-8. doi: 10.1007/s00431-009-1073-2. Epub 2009 Oct 4.
citation: Khan F, Momtaz S, Abdollahi M. The relationship between mercury exposure and epigenetic alterations regarding human health, risk assessment and diagnostic strategies. J Trace Elem Med Biol. 2019 Mar;52:37-47. doi: 10.1016/j.jtemb.2018.11.006. Epub 2018 Nov 14.
citation: Zeitz P, Orr MF, Kaye WE. Public health consequences of mercury spills: Hazardous Substances Emergency Events Surveillance system, 1993-1998. Environ Health Perspect. 2002 Feb;110(2):129-32. doi: 10.1289/ehp.02110129.
citation: Schober SE, Sinks TH, Jones RL, Bolger PM, McDowell M, Osterloh J, Garrett ES, Canady RA, Dillon CF, Sun Y, Joseph CB, Mahaffey KR. Blood mercury levels in US children and women of childbearing age, 1999-2000. JAMA. 2003 Apr 2;289(13):1667-74. doi: 10.1001/jama.289.13.1667.
citation: Park JD, Zheng W. Human exposure and health effects of inorganic and elemental mercury. J Prev Med Public Health. 2012 Nov;45(6):344-52. doi: 10.3961/jpmph.2012.45.6.344. Epub 2012 Nov 29.
citation: Ha E, Basu N, Bose-O'Reilly S, Dorea JG, McSorley E, Sakamoto M, Chan HM. Current progress on understanding the impact of mercury on human health. Environ Res. 2017 Jan;152:419-433. doi: 10.1016/j.envres.2016.06.042. Epub 2016 Jul 18.
citation: Branco V, Caito S, Farina M, Teixeira da Rocha J, Aschner M, Carvalho C. Biomarkers of mercury toxicity: Past, present, and future trends. J Toxicol Environ Health B Crit Rev. 2017;20(3):119-154. doi: 10.1080/10937404.2017.1289834. Epub 2017 Apr 5.
citation: Clarkson TW, Magos L. The toxicology of mercury and its chemical compounds. Crit Rev Toxicol. 2006 Sep;36(8):609-62. doi: 10.1080/10408440600845619.
citation: Clarke D, Buchanan R, Gupta N, Haley B. Amelioration of Acute Mercury Toxicity by a Novel, Non-Toxic Lipid Soluble Chelator N,N'bis-(2-mercaptoethyl)isophthalamide: Effect on Animal Survival, Health, Mercury Excretion and Organ Accumulation. Toxicol Environ Chem. 2012;94(3):616-640. doi: 10.1080/02772248.2012.657199.
citation: Risher JF, Amler SN. Mercury exposure: evaluation and intervention the inappropriate use of chelating agents in the diagnosis and treatment of putative mercury poisoning. Neurotoxicology. 2005 Aug;26(4):691-9. doi: 10.1016/j.neuro.2005.05.004.
citation: George GN, Prince RC, Gailer J, Buttigieg GA, Denton MB, Harris HH, Pickering IJ. Mercury binding to the chelation therapy agents DMSA and DMPS and the rational design of custom chelators for mercury. Chem Res Toxicol. 2004 Aug;17(8):999-1006. doi: 10.1021/tx049904e.
citation: Bose-O'Reilly S, Bernaudat L, Siebert U, Roider G, Nowak D, Drasch G. Signs and symptoms of mercury-exposed gold miners. Int J Occup Med Environ Health. 2017 Mar 30;30(2):249-269. doi: 10.13075/ijomeh.1896.00715. Epub 2017 Mar 22.
citation: Doering S, Bose-O'Reilly S, Berger U. Essential Indicators Identifying Chronic Inorganic Mercury Intoxication: Pooled Analysis across Multiple Cross-Sectional Studies. PLoS One. 2016 Aug 30;11(8):e0160323. doi: 10.1371/journal.pone.0160323. eCollection 2016.